- Home
- KSS vs NUVB Comparison
KSS vs NUVB Comparison
Compare KSS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSS
- NUVB
- Stock Information
- Founded
- KSS 1962
- NUVB 2018
- Country
- KSS United States
- NUVB United States
- Employees
- KSS N/A
- NUVB N/A
- Industry
- KSS Department/Specialty Retail Stores
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- KSS Consumer Discretionary
- NUVB Health Care
- Exchange
- KSS Nasdaq
- NUVB Nasdaq
- Market Cap
- KSS 931.8M
- NUVB 837.0M
- IPO Year
- KSS 1992
- NUVB N/A
- Fundamental
- Price
- KSS $10.74
- NUVB $2.23
- Analyst Decision
- KSS Sell
- NUVB Strong Buy
- Analyst Count
- KSS 13
- NUVB 6
- Target Price
- KSS $8.54
- NUVB $7.83
- AVG Volume (30 Days)
- KSS 21.0M
- NUVB 5.0M
- Earning Date
- KSS 08-27-2025
- NUVB 08-07-2025
- Dividend Yield
- KSS 4.66%
- NUVB N/A
- EPS Growth
- KSS N/A
- NUVB N/A
- EPS
- KSS 1.09
- NUVB N/A
- Revenue
- KSS $16,072,000,000.00
- NUVB $10,957,000.00
- Revenue This Year
- KSS N/A
- NUVB $98.78
- Revenue Next Year
- KSS N/A
- NUVB $489.71
- P/E Ratio
- KSS $9.85
- NUVB N/A
- Revenue Growth
- KSS N/A
- NUVB N/A
- 52 Week Low
- KSS $6.04
- NUVB $1.54
- 52 Week High
- KSS $22.00
- NUVB $3.83
- Technical
- Relative Strength Index (RSI)
- KSS 51.23
- NUVB 46.97
- Support Level
- KSS $11.81
- NUVB $2.46
- Resistance Level
- KSS $21.39
- NUVB $2.76
- Average True Range (ATR)
- KSS 1.47
- NUVB 0.15
- MACD
- KSS -0.11
- NUVB -0.01
- Stochastic Oscillator
- KSS 12.70
- NUVB 21.32
About KSS Kohl's Corporation
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.